Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Uveal Melanoma × Nivolumab × Clear all

Phase

Phase 1 7 Phase 2 6 Phase 1/2 4 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 21 Melanoma 20 Carcinoma, Renal Cell 12 Stomach Neoplasms 8 Lung Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 5 Brain Neoplasms 5 Mesothelioma 4 Kidney Neoplasms 4 Carcinoma, Hepatocellular 4 Adenocarcinoma Of Esophagus 4 Urinary Bladder Neoplasms 3 Neoplasms 3 Neoplasm Metastasis 3 Head and Neck Neoplasms 3 Various Advanced Cancer 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Mesothelioma, Malignant 2 Liver Neoplasms 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Carcinoma 2 Anus Neoplasms 2 Adenocarcinoma 2 von Hippel-Lindau Disease 1 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Thoracic Neoplasms 1

Interventions

Melphalan 3 tebentafusp 1 sargramostim 1 fotemustine 1 aflibercept 1 Ranibizumab 1 Nivolumab 1 Neoadjuvant Therapy 1 Melatonin 1 MART-1 Antigen 1 Ipilimumab 1 Eye Enucleation 1 Colony-Stimulating Factors 1 Chemotherapy, Cancer, Regional Perfusion 1 Brachytherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06519266 2024-11-25

SCANDIUM-III

Vastra Gotaland Region

Phase 3 Recruiting

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡